In September, 2015, Endo International plc (NASDAQ: ENDP) acquired Par Pharmaceutical merging the business with Endo's Qualitest, thereby expanding the generics business to a top industry leader.
Endo is highly focused generics and specialty branded pharmaceutical company delivering quality medicines to patients in need through excellence in development, manufacturing and commercialization. Endo has global headquarters in Dublin, Ireland and U.S. headquarters in Malvern, PA.
» Par Pharmaceutical - Founded in 1978, today the company's sales place it among the leading generic pharmaceutical companies in the United States.*
» Employs approximately 3,700 professionals in offices in Chestnut Ridge, New York; Irvine, California; Rochester, Michigan; Stratford, Connecticut; Chennai, India ; Montebello, and New York.
» An experienced Authorized Generics partner of choice for many of the world's leading pharmaceutical companies.
» Conducts manufacturing in the United States and abroad and markets and/or license more than 200 prescriptions drug products families.
» Strong distribution relationships in place at top U.S. retail chains, wholesalers, distributors, managed care organizations, mail order pharmacies and group purchasing organizations.
» Operational excellence in quality and compliance.
*for the year ending 2016. source :IMS Health.